The COVID-19 jackpot that eluded CSL
CEO Paul Perreault faced a dilemma amid the rush to develop a vaccine for the coronavirus – one that resulted in the biggest disappointment of his career there.
CSL chief executive Paul Perreault faced a devil’s choice when it came to developing a COVID-19 vaccine during the height of the pandemic.
The biotechnology company was backing a vaccine from the University of Queensland, which was showing promise. But then a problem emerged in early-stage trials: the vaccine’s design had triggered false-positive results for HIV infections.
Loading...
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Liam WalshReporterLiam Walsh writes on investigations and companies with The Australian Financial Review. He has won multiple media awards, worked in Japan and is now based in Brisbane. Email Liam at liam.walsh@afr.com.au
Latest In Healthcare & fitness
Fetching latest articles